奥扎格雷注射剂联合长春西汀注射剂治疗脑卒中患者的临床研究

发布时间：2018-03-24 23:20

本文选题：奥扎格雷　切入点：长春西汀　出处：《中国临床药理学杂志》2017年13期

【摘要】：目的观察奥扎格雷联合长春西汀对脑卒中患者的临床疗效和安全性。方法 120例脑卒中患者随机分为试验组60例和对照组60例,2组患者均予以常规治疗。对照组在常规治疗基础上静脉滴注奥扎格雷钠160 mg qd,试验组在对照组基础上静脉滴注长春西汀30 mg qd,2组患者均连续用药14 d。比较2组患者临床疗效日常生活能力评分(ADL)、美国国立卫生院卒中量表(NIHSS)评分,并检测2组纤维蛋白原、凝血酶原时间、活化部分凝血凝血酶原时间(APTT)、血小板计数、血小板分布宽度、血小板平均体积及药物不良反应发生率。结果治疗后,试验组和对照组的总有效率分别为91.67%(55/60例)和76.7%(46/60例),ADL评分分别为(58.53±9.37),(53.52±8.80)分,NIHSS评分分别为(6.67±2.12),(8.28±2.83)分,血小板分布宽度分别为(17.41±3.60)%,(20.52±3.89)%,血小板平均体积分别为(7.12±0.43)%,(8.17±0.52)%,纤维蛋白原分别为(3.43±0.59),(3.75±0.68)g·L~(-1),差异均有统计学意义(均P0.05)。试验组的药物不良反应主要有紫癜2例和皮疹1例,对照组的药物不良反应有皮疹1例。试验组和对照组的药物不良反应发生率分别为5.00%(3/60例)和1.67%(1/60例),差异无统计学意义(P0.05)。结论奥扎格雷联合长春西汀能够抑制血小板活化,改善脑卒中患者神经功能,安全性较高。
[Abstract]:Objective to observe the clinical efficacy and safety of ozagrel combined with vinpocetine in the treatment of stroke. Methods 120 stroke patients were randomly divided into experimental group (n = 60) and control group (n = 60). On the basis of routine treatment, ozagrel sodium 160mg QD was injected intravenously, and vinpocetine 30mg QDX was given intravenously for 14 days in the experimental group and the control group. The ADL scores of the two groups were compared, and the scores of ADL were compared between the two groups. The National Institutes of Health Stroke scale (NIHSS) score, Fibrinogen, prothrombin time, activated partial thromboplastin time (APTTT), platelet count, platelet distribution width, mean platelet volume and incidence of adverse drug reactions were measured. The total effective rate of the test group and the control group was 91.67 / 55 / 60) and the ADL score of 76.7A / R / 46 / 60 was 58.53 卤9.37 / 53.52 卤8.80 respectively. The NIHSS score was 6.67 卤2.12 (8.28 卤2.83), respectively. The distribution width of platelets was 17.41 卤3.60 and 20.52 卤3.89, the mean volume of platelets was 7.12 卤0.43 and 8.17 卤0.52, respectively, and the fibrinogen was 3.43 卤0.59g / L, respectively. The difference was statistically significant (P 0.05). The main adverse drug reactions in the test group were purpura in 2 cases and rash in 1 case. The incidence of adverse drug reactions in control group and control group were 5.00 / 60 and 1.67 / 1 / 60 respectively, with no significant difference (P 0.05). Conclusion Ozagrel combined with vinpocetine can inhibit platelet activation. It is safe to improve the neurological function of stroke patients.
【作者单位】：宁波市康复医院神经康复二科;绍兴市人民医院急诊科;
【基金】：浙江省卫生适宜技术成果转化计划基金资助项目(2011ZHA011)
【分类号】：R743.3

【相似文献】